AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

21 stories found

A luminous painted lung-shaped garden of cells and branching paths, representing a research map of tumor diversity.
Social good & healthGermany+1 clusters01

The tumor looks early. Its cells may tell another story.

An early-stage tumor is not necessarily a low-risk tumor. A new lung-cancer atlas offers an encouraging way to investigate the difference, without pretending that a better prediction is already a better treatment. Researchers from LMU, Charité and BIFOLD linked molecular profiles from archived tumor tissue to patients' clinical histories. The LuCaS+ work covers 454 patients and more than 2.5 million cell nuclei. Machine-learning methods helped identify cell groups and patterns in the surrounding tissue associated with how disease progressed. The researchers report validation in a separate patient cohort. The value is not simply the size of the dataset. A tumor contains different populations of cells, and its neighbors—immune cells, connective tissue and blood vessels—also matter. Combining that information could help explain why tumors that look similar under conventional staging can behave differently. This deserves attention as a constructive use of AI: extracting clinically relevant patterns from complex evidence rather than generating another confident answer. The research atlas is available to other scientists, creating opportunities to inspect, extend and challenge the work. But the boundary is essential. Archived samples and follow-up data can support a prognostic model; they cannot show that changing care on its advice improves survival or avoids unnecessary treatment. Prospective evaluation and testing in broader populations remain necessary before routine clinical decisions should depend on it. For patients, the promise is more discriminating care. The risk is turning a research classification into unwarranted certainty. The right next headline would be evidence that using the model helps people—not just that it predicts a category more accurately.

3 min
Layers of translucent teal and blue paper form a brain above a slide speckled with violet marks. This is a concept illustration, not a patient scan.
Social good & healthInternational research cohorts+1 clusters02

Which children could safely get less radiation? A tumor test offers a clue

A family dealing with a childhood brain tumor faces two different futures at once. Parents want the treatment most likely to keep the cancer from coming back. They also want to protect the child who will have to live with what that treatment does to memory and learning. A new Nature Genetics study offers a way to ask more precisely which children might benefit from less radiation. The researchers built MANTIS using tumor DNA methylation profiles from 2,786 patients across two diseases, medulloblastoma and ependymoma. Methylation marks are chemical tags on DNA; many centers already use the patterns to help classify brain tumors. MANTIS uses those data to estimate an individual survival curve over ten years. The medulloblastoma model was validated in three separate clinical-trial cohorts totaling 898 patients. That is a test against real follow-up data, not a trial in which a model chose a child’s treatment. The team then revisited radiation doses for average-risk medulloblastoma. Its analysis singled out roughly 60% of the patients studied in that setting as possible candidates for lower-dose radiation to the brain and spine. The researchers did not detect a statistically significant survival disadvantage in that selected group; lower doses were associated with better cognitive outcomes. A difference too small to detect in one analysis can still matter enormously to a child. The promising result is a testable way to select patients for a trial, not evidence that six in ten children receiving cancer care should have treatment reduced.

4 min
A paper diptych separates a street camera watching pedestrians from an older adult discussing a design at a round table.
PrivacyAustralia / United States+1 clusters03

Police counted nine wrong face alerts. Out of how many?

Western Australia’s police force published a number that could disappear on a dashboard: 0.00065%. That was the proportion of face scans that produced an alert police classified as incorrect. Imagine looking over the shoulder of the officer who actually received an alert, though. That officer saw one of 292 alerts, not one of 1,380,882 scans. Nine incorrect alerts out of 292 is about 3.1%. The numerator never moved. The question did. The trial ended October 31 after 100 deployments at 43 locations. Police reported 122 arrests during deployments and said officers reviewed potential matches. A scan isn’t a unique individual, an alert isn’t an arrest and an arrest isn’t a conviction. Nor can either percentage tell us how often the system failed to notice someone on the watchlist. Calculating that would require knowing how many such people passed the cameras, including the ones the cameras missed. A separate US paper offers a useful way to think about who gets counted before technology reaches the street or the home. Researchers reviewed documents describing 100 projects funded by the National Institute on Aging. Few explicitly described involving end users in design or targeting underserved populations. That is evidence about what the project documents recorded. It does not establish that patients were harmed, and the researchers did not evaluate the Australian cameras. The common question is whose experience the chosen measure leaves out. For a person wrongly approached in public, the outcome is the encounter, not a near-zero percentage on a slide.

4 min
A folded protein ribbon and a rain-swept mountain landscape sit on opposite sides of an ivory field.
Social good & healthGlobal / Nepal+2 clusters04

From a protein to a hillside, AI narrows where to look

Choosing what to test next can be valuable even when a model cannot make the final decision. Two peer-reviewed studies published October 31 show what that looks like at very different scales: a protein small enough to help deliver messenger RNA, and a district large enough to plan for monsoon damage. DeepDelivery screened human proteins and nominated 512 candidates. The researchers selected 15 for experimental testing. Twelve worked as scaffold components in an engineered system that formed particles and delivered mRNA. That is a wet-lab result, not just a score assigned by another algorithm. The denominator matters: twelve of fifteen selected for testing, not twelve of all 512, and not an 80% success rate in patients. A protein component with useful properties is not a finished treatment. In Nepal, a separate team combined terrain, recent rainfall and rainfall forecasts to estimate which districts might experience landslide impacts within a 14-day window. It trained its models on 2016–2022 records and tested against the 2023 and 2024 monsoons. The authors report F1 scores of at least 0.7. That number combines precision and recall: how often warnings correspond to recorded impacts and how many recorded impacts the model catches. It is not a 70% probability that a specific hillside will collapse. A laboratory can afford to try several candidates that fail. A district deciding where to position supplies faces a different cost for a missed warning or repeated false alarms. The common achievement is making the next decision more focused. The next test must belong to the people making that decision.

4 min
Ink-wash diagnostic lens bringing case cards into focus while a larger human silhouette remains incomplete.
Social good & healthGlobal+1 clusters05

A striking diagnosis score. Not a licence to replace doctors.

Microsoft's diagnostic result deserves excitement and a careful reading. In its October 22 account of the research, Microsoft reports that MAI-DxO reached 83% diagnostic accuracy on complex New England Journal of Medicine cases, compared with 36% for physicians allowed external reference resources. The company also reports a strong result on a separate set of emergency-department cases. These are promising results for a system that works through diagnostic questions, rather than simply guessing from a finished vignette. But the setting matters. The comparisons used controlled simulations and historical cases, not a prospective trial showing improved outcomes for patients receiving care. Generalist physicians are not the same comparator as a specialist team with a physical examination, a full clinical workflow and responsibility for treatment. Microsoft's benchmark documentation also explains that its gatekeeper can supply plausible information when the underlying case record does not contain a requested detail. That does not make the experiment worthless. Controlled comparisons help identify capabilities worth testing. It does mean that a diagnostic score should not silently become a claim about clinical safety, replacement of clinicians or money already saved in hospitals. The encouraging next step is the one Microsoft itself describes: prospective evaluation with Beth Israel Deaconess. Our question is not whether an AI can look impressive on a benchmark. It is whether assistance improves decisions and outcomes when the patient, the uncertainty and the consequences are real.

4 min
A hand selects a lens beside a notebook, representing clinical checking and independent understanding.
Social good & healthGlobal+2 clusters06

A better AI answer can still need a better human check.

There is something genuinely encouraging in the new clinical reasoning study: the human check was not merely ceremonial. It helped improve the result. There is also a warning against judging a system by the right answers alone. The Nature Communications paper compares six matched pairs of reasoning and standard language models on retrospective clinical records. Reasoning models were better at including the primary diagnosis, but they also suggested more false-positive diagnoses. A separate validation exercise with fifteen physicians found benefits from structured collaboration. These are controlled retrospective findings, not proof of improved outcomes for patients in routine care. That distinction changes the design question. A longer list of plausible diagnoses can help a clinician consider something overlooked. It can also create unnecessary work if the extra possibilities are treated as conclusions. The quality of the workflow depends on how suggestions are challenged, not just how many the model can produce. The second paper, in Communications Psychology, addresses a related but different problem. Its SYNC framework separates performance with AI assistance from durable human learning. It is a Perspective proposing mechanisms and practices, not a new trial proving that a particular intervention works. I read the two together as an invitation to ask three questions. Did assistance improve the task? Were the additional errors caught? Can the person still explain and apply the reasoning without the tool later? The clinical paper offers evidence relevant to the first two. The learning framework gives a vocabulary for investigating the third. That is an editorial comparison, not a claim that one study validates the other. We can welcome useful assistance while refusing to let a polished answer stand in for either safety or understanding.

4 min
A young person at a window has both a phone and possible human connections beyond it.
Social good & healthGlobal+2 clusters07

Some teenagers find AI support helpful. Many still want more help.

If a young person says a conversation helped, I think we should listen. We should also ask the next question: did they get the support they still needed afterwards? A new peer-reviewed study of 24,132 students in England offers an unusually useful distinction. Past-year use of general-purpose AI for mental-health support was reported by 662 students, or 2.7%. Among those answering the helpfulness question, 324 of 580—55.9%—called it helpful. But 410 of 649 respondents to a different question, or 63.2%, wanted additional support. The denominators differ and should not be merged. Most AI users, 610 of 662, also accessed other support. That makes a simple replacement story unconvincing. The chatbot may be one place a person turns within a larger, incomplete support network. The study does not establish that AI caused their difficulties, improved a clinical condition or displaced human care. There is room here for both empathy and caution. Dismissing every helpful interaction would dismiss the experience being reported. Selling that experience as proof of treatment effectiveness would ask it to carry evidence it does not contain. A useful institutional response would investigate who cannot obtain sufficient help, how young people move between digital and human support, and whether referrals actually lead somewhere. This accepted article was published on October 27, but the accessible abstract does not establish the survey field dates. Its percentage should not be presented as a current national adoption estimate.

3 min
Conceptual Texas data-center landscape with alternative combustion and renewable power routes, representing modeled choices.
EnvironmentTexas, United States+3 clusters08

Texas data-center power choices could reverse decades of emissions cuts

HARC's Texas assessment asks how rising data-center electricity demand could change emissions under different power-supply choices. Its modeled range is wide enough that some paths threaten to reverse substantial cuts in emissions, while others add far less pollution. These are conditional projections. They are not measurements of pollution from facilities that have not yet been built, and they should not be presented as an inevitable statewide outcome. The consequential finding is the sensitivity to the supply decision. A community evaluating a project needs to know more than its advertised computing capacity. It needs to know which sources will actually serve the load, what controls they use and how often they operate. A claim about the eventual grid mix may not answer what happens during an interim period of on-site generation. The method also sets limits on the conclusion. HARC scales a representative facility, assumes a utilization level and projects capacity and emissions trends. Delayed projects, different designs or a changing grid would shift the result. Emissions totals also do not directly tell us the pollution concentration at an individual home or the health outcome of a particular resident. That uncertainty is a reason to make decisions observable. Publish the expected operating profile, the permit conditions and the monitoring results. Communities can then compare promises with performance. The study is most useful as a warning about choices that remain open, rather than a dramatic number detached from the assumptions that produce it.

5 min
A clinician compares overlapping prostate-cancer risk maps before a radiotherapy decision.
Social good & healthSweden+2 clusters09

A prostate-cancer AI reordered risk, but has not proved better care

A better-looking risk chart is not yet a better treatment for a patient. A new Scientific Reports study tested a previously developed multimodal AI model on 353 people receiving radiotherapy for localized prostate cancer in the STHLM3 cohort. The model combined clinical features and biopsy-slide information and produced a different risk ordering from the European Association of Urology categories. For biochemical recurrence, its concordance index was 0.65 versus 0.60 for the EAU scheme. The reported difference did not meet conventional statistical significance, with p = 0.09. Comparisons for high-risk biochemical recurrence and prostate-cancer-specific mortality were also not statistically significant. The study did find exploratory variation inside the conventional high-risk group: a subset labeled low-risk by AI had no observed biochemical recurrence over ten years, while another subset did substantially worse. That may be worth pursuing, but it is not a license to de-escalate therapy today. The threshold was determined within this radiotherapy cohort, events were limited, and the population was linked to the same broader research setting used during model development. Independent external validation and prospective tests of treatment decisions are still needed. A patient might reasonably ask, 'Would this change what my doctor does, and would that help me?' The current paper cannot answer that outcome question. Its real contribution is a testable hypothesis about who needs more or less treatment, with a clear warning that promising stratification must survive clinical trials before becoming a care rule.

7 min
A researcher examines imaging slices with warm brown-fat signals while a separate mouse study remains in the background.
Social good & healthUnited States+2 clusters10

AI helped map brown fat in thousands of scans. The drug clue is not a cure.

An existing blood-pressure medicine has become an intriguing candidate in brown-fat research, but the evidence has not crossed into a human treatment claim. In a peer-reviewed Nature study, researchers analyzed imaging and records from 101,243 patients at a large cancer center. Brown fat, which spends energy producing heat, was associated with lower prevalence of several cardiovascular and psychiatric diagnoses. Machine learning allowed the team to semi-automatically quantify brown-fat activity in roughly 8,700 patients. Higher activity, particularly in one underarm depot, correlated with lower odds of cardiometabolic disease and a healthier distribution of white fat. Medication records then pointed to a class of blood-pressure drugs. Follow-up tests found that losartan increased brown-fat cell activity and energy expenditure in mice. That sequence matters: the AI analysis helped move from a broad clinical pattern to a specific, experimentally testable mechanism. It also sets a firm boundary. These patients were not randomized to change brown-fat activity; they were drawn from a cancer center; and the losartan result was not a trial showing improved human outcomes. The NIH describes it as a possible route to future drug repurposing, not a current indication. Patients should not alter medication because of a headline. The next evidence should be replication in other populations and prospective testing that measures patient outcomes, dosage and adverse effects. The real success of AI here is accelerating a scientific question without pretending the answer is finished.

6 min
An empty operating room with a transparent clinical checklist faces an illuminated semiconductor fabrication plant beyond glass.
Social good & healthSouth Korea / Global+3 clusters11

AI chips are minting profit. Surgical AI still has a much thinner evidence base

Two numbers in today's sources deserve to be held side by side without pretending they belong to the same transaction. Samsung's preliminary guidance puts third-quarter operating profit at 107.4 trillion won, nearly nine times the year-earlier figure, as demand and prices for AI-related memory support earnings. These are projected company results, with a detailed divisional breakdown due later; they do not measure the social value delivered by every AI application. Separately, a peer-reviewed scoping review in npj Digital Surgery searched five databases and identified 3,020 records on intraoperative AI clinical decision support. Only five studies met its specific inclusion criteria: one completed feasibility study and four ongoing prospective studies or registries. That does not mean only five AI-in-surgery studies exist, and it does not show these systems are unsafe. It means the prospective clinical and ethical evidence under this review's narrow question remains early. The contrast is about timing and incentives. Markets can reward the infrastructure that makes AI possible long before clinical systems have demonstrated safety, equity, consent and real patient benefit under routine conditions. A chip supplier is not responsible for conducting every surgical trial, and clinical validation properly takes longer than a quarterly earnings report. Still, the scale of investment creates a public expectation: buyers and hospitals should demand prospective outcomes and override procedures before live recommendations influence care. The impressive profit is real as a company forecast. The patient benefit is a separate question that must be tested.

7 min
A patient reviews clear AI-prepared questions before meeting a surgeon, with an anxiety gauge and consultation timer both falling.
Social good & healthChina+4 clusters12

A local AI briefing cut pre-surgery anxiety and physician workload

A randomized phase II study offers a bounded example of medical AI that helped without pretending to replace the clinician. Researchers assigned 268 people newly diagnosed with prostate cancer and scheduled for radical prostatectomy to standard communication or an AI-assisted pathway. The intervention used a locally deployed large language model to prepare personalized answers to patient questions before the routine face-to-face discussion. Physicians remained responsible for the encounter and were blinded to group assignment. The AI-assisted group reported a mean post-communication GAD-7 anxiety score of 3.2, compared with 5.7 in the control group. Physician workload on the NASA-TLX scale averaged 39.9 versus 56.8, and routine communication time fell from 19.9 to 11.3 minutes. Satisfaction, emotions, and illness perceptions also improved. This is stronger evidence than a product testimonial, but it is not a general verdict on AI in medicine. The study was conducted at one cancer center, used a specific preoperative setting, measured near-term outcomes, and does not establish diagnostic accuracy, surgical outcomes, or long-term safety. The trial registry also still shows an earlier estimated enrollment of 160 and future completion dates, while the published paper reports 268 randomized participants; that record mismatch should be clarified. The design’s most important feature is the boundary: the model answered common questions in advance, responses were reviewed, and the surgeon still conducted the consent conversation. AI did not replace the relationship. It gave the relationship a better starting point.

10 min
An ordinary chest CT reveals a small illuminated esophageal lesion while an AI triage path directs the patient toward confirmatory endoscopy.
Social good & healthChina and international validation sites+4 clusters13

AI found hidden esophageal cancers in CT scans patients already had

A multicenter Nature Medicine study reports that an AI system called EAGLE can identify esophageal cancer and precancerous lesions in noncontrast chest CT scans that were not acquired specifically for the esophagus. The model was trained on 6,813 patients and validated across 12 centers in three countries involving 80,612 patients. In external cohorts totaling 11,466 people, it reached 90.0 percent sensitivity for cancer and 98.5 percent specificity, while sensitivity for precancerous lesions was lower at 52.5 percent. A calibration cohort of 35,402 patients reduced false positives by 72.7 percent while preserving sensitivity. In a prospective hospital cohort of 17,446 patients, 38 of 90 positive predictions were true positives, producing a 42.2 percent positive predictive value and 87.8 percent sensitivity for cancer. A real-world low-dose screening cohort of 10,959 people reported 99.94 percent specificity. The opportunity is unusually practical: use scans already being performed to identify people who should receive confirmatory endoscopy. But the strongest efficiency claims remain modeled. Simulations suggested triage could triple detection, reduce diagnostic time by 70.4 percent, and lower costs in seven of eight countries. Those are not randomized outcomes or evidence of reduced mortality. Most data came from China, follow-up was under two years, endoscopy adherence was limited, and broader validation is needed for different disease patterns. EAGLE may make existing imaging more valuable. It has not yet proved that population deployment improves survival or avoids harmful overdiagnosis.

10 min
A bright conversational knowledge pathway rises beside a closed clinical decision gate that remains in the same position.
Social good & healthJapan+3 clusters14

An HPV chatbot improved vaccine literacy without changing vaccination decisions

A randomized clinical trial in Japan found that an AI chatbot modestly improved HPV vaccine literacy compared with a standard government leaflet, but it did not measurably change caregivers' vaccination decisions after two weeks. The trial randomized 848 female caregivers of unvaccinated daughters aged 12 to 18. Its modified intention-to-treat analysis included 704 participants immediately and 477 at the two-week literacy follow-up. After adjustment, the chatbot group scored 0.30 points higher on a seven-point literacy scale at both time points. The decision result was different: 40.3 percent of assessed caregivers in the chatbot group and 39.6 percent in the leaflet group met the study's decision-to-vaccinate definition, with no statistically significant difference. The chatbot used GPT-4o with a Japan-specific library drawn from official and peer-reviewed material, stayed within a defined scope, and directed personal clinical questions to professionals. This is useful causal evidence for a narrow intervention, not proof that general-purpose chatbots improve health behavior. Attrition was substantial, participants were all female caregivers recruited online, most had college or university education, and follow-up was short. The clearest lesson is not that the chatbot failed. It is that knowledge and action are different outcomes. Scalable conversation may strengthen literacy, while trust, clinician relationships, access, and social context still determine what people do.

9 min
A sterile robotic wet lab connects an AI experiment planner to pipettes and culture plates while a scientist holds a physical safety interlock over one amber anomaly.
Social good & healthUnited States+4 clusters15

Anthropic builds a wet lab as it explores AI-directed biology

Anthropic has confirmed that it is establishing a wet laboratory in the San Francisco Bay Area and exploring whether Claude can direct robotic equipment with limited human intervention. The company's life-sciences leadership told Reuters that biology ultimately requires experiments in the physical world and that human oversight remains essential. Anthropic says the laboratory is not specifically a drug-discovery facility, has not disclosed its exact work, and is not running clinical trials. Its broader ambitions include tools for rare, neglected, and currently difficult-to-treat conditions, while its Model Hardware Standard is intended to help AI systems communicate with laboratory equipment. The company also acquired Coefficient Bio; Reuters reported a roughly $400 million stock price based on a source, but Anthropic confirmed the acquisition without confirming the amount. The opportunity is substantial: an AI system that can design an experiment, interpret results, and revise the next run could compress research cycles. The risk also changes when text output becomes physical action. A hallucinated protocol, contaminated sample, unsafe reagent combination, or overconfident biological inference can propagate through automation before a person notices. Governance should therefore attach to the closed loop, not only the model. Every AI-directed experiment needs bounded hardware permissions, validated protocols, chain-of-custody logs, biological screening, anomaly detection, and a human stop authority that remains effective when the system proposes the next step faster than a scientist can review it.

8 min
A transparent lung scan and clinical evidence panel pass through several hospital environments while a performance signal changes between sites.
Social good & healthEurope+2 clusters16

Explainable AI improved oncologists’ lung-cancer predictions, but external validation exposed the limits

A multi-country study in Nature Medicine evaluated explainable AI support for treatment decisions in advanced non-small-cell lung cancer. The retrospective I3LUNG cohort included 2,396 patients treated with immunotherapy-based regimens across six centers in six countries. Models using routine clinical and blood data achieved test performance up to an area under the curve of 0.77 and outperformed traditional single biomarkers and clinical scores in the independent test set. In a separate usability study, twenty oncologists reviewed one hundred cases first without and then with model predictions and SHAP-based explanations. Sensitivity for predicting disease control increased from 0.72 to 0.87, with gains in accuracy and F1 performance; overall-survival prediction improved more modestly. The paper is valuable because it reports the limits alongside the gains. External-validation performance fell to an AUC range of 0.55 to 0.72, the complete multimodal sample was small, and added imaging, pathology, and genomic data did not produce a reliable benefit across test and external cohorts. Differences between patient populations may explain some decline, which is exactly why local calibration and prospective evaluation matter. The authors describe silent prospective validation in more than two thousand patients, another usability study, and a planned pragmatic randomized trial before deployment. The result is promising decision support, not autonomous clinical authority.

7 min
Six protein biomarker dials converge on an experimental molecule above a lung scan while an unfinished trial path continues into shadow.
Social good & healthGlobal+2 clusters17

An AI-discovered lung drug shifted six aging clocks, not human lifespan

An experimental drug developed with AI has produced a result that is scientifically interesting and extremely easy to oversell. Rentosertib was designed for idiopathic pulmonary fibrosis, a progressive scarring disease of the lungs. Its target was identified with AI and its molecule was generated through an AI-driven discovery platform. Researchers analyzed protein data from 42 patients in a 12-week phase 2a trial and applied six independently developed proteomic aging clocks. All six estimated a reduction in predicted biological age among treated patients. Earlier trial results also showed a promising dose-related improvement in forced vital capacity, an important lung-function measure. Agreement across multiple clocks makes the signal less likely to be an artifact of one aging model. It does not prove that the drug extends life, reverses aging throughout the body, or is safe and effective as a longevity treatment. The cohort was small, the follow-up was short, the participants had a serious age-related disease, and improving inflammation or fibrosis can change proteins used by aging clocks. The Nature Biotechnology paper also discloses that several authors work for the company developing the drug and that its company leader is an author. The responsible interpretation is neither miracle nor dismissal. This is a hypothesis-generating biomarker result attached to a candidate that has advanced in clinical development. Larger, longer, independently scrutinized trials should prespecify aging endpoints and connect them with functional outcomes, safety, disease progression, and eventually survival. AI accelerated the discovery path. Biology still decides whether the claim survives.

5 min
A cinematic museum-at-night installation shows an automated factory of occupations stopping at a velvet rope around a warm human care chair and joined hands.
Work & marketsGlobal+5 clusters18

A technology optimist asks society to reserve some work for humans

A New York Times report and a new long-form essay mark a sharp change in the tone of one of technology's best-known optimists. The warning focuses on three overlapping risks: AI-enabled security threats such as hacking, biological misuse, and fraud; job destruction across cognitive and physical work; and harm to children's learning and human relationships. The argument is not that AI lacks benefits. It is that governments have no adequate architecture for a transition that could move faster than earlier industrial changes. One proposal is a Human Reserved domain: jobs or tasks society deliberately protects for people even when AI or robots could do them, with care work as the clearest example. The author also calls for national coordination across employment, education, taxation, health, security, and other systems, plus international cooperation. These are proposals, not settled policy, and they raise difficult enforcement and distribution questions. Their importance is the principle that technical capability does not automatically authorize replacement.

5 min
A precise national-policy dossier shows AI benefits passing through signed safety, worker-support, and human-control checkpoints before a scale gate opens.
Law & informationSingapore+4 clusters19

Singapore puts human control at the center of national AI adoption

Singapore’s 2026 National Day Rally framed AI adoption as a national bargain rather than an unrestricted technology race. The prime minister highlighted AI agents for small businesses, personalized exercise plans, breast-cancer screening support, genomics, and autonomous-vehicle trials. He also said adoption should not run ahead of the country’s ability to retrain and support affected workers, that autonomous vehicles should scale only after safety is proven, and that people must remain in control as capable agents create harder-to-predict risks. The speech committed Singapore to practical safeguards at home and coalitions for international rules, while stopping short of specifying every enforcement mechanism or timetable. The value of the approach is its sequence: prove the system, govern the risk, support the people disrupted, then scale. That standard now needs measurable implementation through named regulators, published stop conditions, worker outcomes, incident disclosure, and public evidence that human control is operational rather than ceremonial.

5 min
A wall of 1,357 medical-device approval tiles narrows to three illuminated patient-outcome records beside an empty hospital evidence chart.
Social good & healthUnited States · Global implications+3 clusters20

Only three of 1,357 FDA-authorized AI medical devices were evaluated on patient outcomes

A PLOS Digital Health evidence census linked the FDA's 1,357 authorized AI and machine-learning medical devices through December 5, 2025 to prospective trials and publications. Thirty-four devices were linked to registered prospective trials, 12 had posted results, 12 had peer-reviewed publications, and only three evaluated patient-centered outcomes such as mortality, morbidity, or readmission. The review does not show that the remaining devices are ineffective; it shows that authorization and benchmark performance rarely answer the outcome question patients care about most. With 78 percent of the devices concentrated in radiology and vulnerable populations often excluded from studies, the validation gap can travel through hospitals and across countries long before durable benefit or equitable performance is known.

5 min
A clinical waveform and reinforcement-learning decision tree ending at an evidence gap.
Cognition & learningGlobal+2 clusters21

Tang et al., “Reinforcement learning for treatment decision-making in sepsis: a scoping review”

Reviewing 72 studies of reinforcement-learning systems for sepsis treatment, the authors found that every study was retrospective, 58 studies—80.6%—relied on the same MIMIC critical-care database, and only 10 used private datasets. Although many papers claimed that AI-derived treatment policies outperformed clinicians, variation in how patient states, treatment actions, rewards, and counterfactual outcomes were defined made those comparisons difficult to validate.

2 min